COVID-19 Outcomes in 4712 consecutively confirmed SARS-CoV2 cases in the city of Madrid.
Heili-Frades, S.; Minguez, P.; Mahillo-Fernandez, I.; Prieto-Rumeau, T.; Herrero Gonzalez, A.; de la Fuente, L.; Rodriguez Nieto, M. J.; Peces-Barba Romero, G.; Peces-Barba, M.; Carballosa de Miguel, M. d. P.; Fernandez Ormaechea, I.; Naya Prieto, A.; Ezzine de Blas, F.; Jimenez Hiscock, L.; Perez Calvo, C.; Santos, A.; Munoz Alameda, L. E.; Romero Bueno, F.; Hernandez-Mora, M. G.; Cabello Ubeda, A.; Alvarez Alvarez, B.; Petkova, E.; Carrasco, N.; Martin Rios, D.; Gonzalez Mangado, N.; Sanchez Pernaute, O.
Show abstract
There is limited information describing features and outcomes of patients requiring hospitalization for COVID19 disease and still no treatments have clearly demonstrated efficacy. Demographics and clinical variables on admission, as well as laboratory markers and therapeutic interventions were extracted from electronic Clinical Records (eCR) in 4712 SARS-CoV2 infected patients attending 4 public Hospitals in Madrid. Patients were stratified according to age and stage of severity. Using multivariate logistic regression analysis, cut-off points that best discriminated mortality were obtained for each of the studied variables. Principal components analysis and a neural network (NN) algorithm were applied. A high mortality incidence associated to age >70, comorbidities (hypertension, neurological disorders and diabetes), altered vitals such as fever, heart rhythm disturbances or elevated systolic blood pressure, and alterations in several laboratory tests. Remarkably, analysis of therapeutic options either taken individually or in combination drew a universal relationship between the use of Cyclosporine A and better outcomes as also a benefit of tocilizumab and/or corticosteroids in critically ill patients. We present a large Spanish population-based study addressing factors influencing survival in current SARS CoV2 pandemic, with particular emphasis on the effectivity of treatments. In addition, we have generated an NN capable of identifying severity predictors of SARS CoV2. A rapid extraction and management of data protocol from eCR and artificial intelligence in-house implementations allowed us to perform almost real time monitoring of the outbreak evolution.
Matching journals
The top 5 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Development and validation of a clinical risk score to predict the risk of SARS-CoV-2 infection from administrative data: a population-based cohort study from Italy 93%
- Lack of protective effect of chloroquine derivatives on COVID-19 disease in a Spanish sample of chronically treated patients 93%
- Epidemiology, risk factors and clinical course of SARS-CoV-2 infected patients in a Swiss university hospital: an observational retrospective study 92%
Similar papers in this journal
Similar papers in this journal
- Development and performance of a population-based risk stratification model for COVID-19 93%
- Differential features of the fifth wave of COVID-19 associated with vaccination and the Delta variant in a reference hospital in Catalonia, Spain 93%
- Spread of the SARS-CoV-2 UK-variant in the South East of France: impact on COVID-19 patients’ age, comorbidity profiles and clinical presentation 93%
Similar papers in this journal
- The potential role of IL-6 in monitoring severe case of coronavirus disease 2019 89%
- SARS-CoV-2 Worldwide Replication Drives Rapid Rise and Selection of Mutations across the Viral Genome: A Time-Course Study Potential Challenge for Vaccines and Therapies 87%
- Diagnostic host gene signature to accurately distinguish enteric fever from other febrile diseases 86%
Similar papers in this journal
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.